Evaluating the Therapeutic Potential of Cenicriviroc in the Treatment of Nonalcoholic Steatohepatitis with Fibrosis: A Brief Report on Emerging Data

Maria Paula Diaz Soto,1 Joseph K Lim2 1Department of Medicine, Yale School of Medicine, New Haven, CT, USA; 2Yale Liver Center and Section of Digestive Diseases, Yale School of Medicine, New Haven, CT, USACorrespondence: Joseph K LimProfessor of Medicine, Yale Liver Center and Section of Digestive D...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Diaz Soto MP, Lim JK
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	cenicriviroc fatty liver non-alcoholic steatohepatitis liver fibrosis antifibrotic therapy clinical trials Diseases of the digestive system. Gastroenterology RC799-869
Acceso en línea:	https://doaj.org/article/4cb2a65da7ce4a4da3a22e9ab8eb02c3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4cb2a65da7ce4a4da3a22e9ab8eb02c3
record_format	dspace
spelling	oai:doaj.org-article:4cb2a65da7ce4a4da3a22e9ab8eb02c32021-12-02T11:08:21ZEvaluating the Therapeutic Potential of Cenicriviroc in the Treatment of Nonalcoholic Steatohepatitis with Fibrosis: A Brief Report on Emerging Data1179-1535https://doaj.org/article/4cb2a65da7ce4a4da3a22e9ab8eb02c32020-08-01T00:00:00Zhttps://www.dovepress.com/evaluating-the-therapeutic-potential-of-cenicriviroc-in-the-treatment--peer-reviewed-article-HMERhttps://doaj.org/toc/1179-1535Maria Paula Diaz Soto,1 Joseph K Lim2 1Department of Medicine, Yale School of Medicine, New Haven, CT, USA; 2Yale Liver Center and Section of Digestive Diseases, Yale School of Medicine, New Haven, CT, USACorrespondence: Joseph K LimProfessor of Medicine, Yale Liver Center and Section of Digestive Diseases, Yale School of Medicine, 333 Cedar Street, LMP 1080, New Haven, CT 06520-8019, USATel +1 (203) 737-6063Fax +1 (203) 785-7273Email joseph.lim@yale.eduAbstract: Non-alcoholic steatohepatitis (NASH) is associated with significant morbidity and mortality due to liver cirrhosis, liver failure, and hepatocellular carcinoma, and represents a leading indication for liver transplantation in the United States (U.S.). A growing spectrum of novel therapies are currently in clinical development and target several mechanisms of action which address hepatic steatosis, steatohepatitis, and hepatic fibrosis. Cenicriviroc (Allergan, Dublin, Ireland) is a novel oral antagonist of CC-motif chemokine receptors 2 and 5 (CCR2/5) which have demonstrated expression on circulating monocytes and Kupffer cells. Preclinical models have confirmed that CCR2/5 antagonism may block fat accumulation and Kupffer cell activation and disrupt monocyte/macrophage recruitment and hepatic stellate cell activation responsible for fibrogenesis. Herein we review results from the phase 2b CENTAUR trial and study designs for the phase 2b TANDEM and phase 3 AURORA trials and discuss the potential role of cenicriviroc in future pharmacotherapy for NASH fibrosis.Keywords: cenicriviroc, fatty liver, non-alcoholic steatohepatitis, liver fibrosis, antifibrotic therapy, clinical trialsDiaz Soto MPLim JKDove Medical Pressarticlecenicrivirocfatty livernon-alcoholic steatohepatitisliver fibrosisantifibrotic therapyclinical trialsDiseases of the digestive system. GastroenterologyRC799-869ENHepatic Medicine: Evidence and Research, Vol Volume 12, Pp 115-123 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	cenicriviroc fatty liver non-alcoholic steatohepatitis liver fibrosis antifibrotic therapy clinical trials Diseases of the digestive system. Gastroenterology RC799-869
spellingShingle	cenicriviroc fatty liver non-alcoholic steatohepatitis liver fibrosis antifibrotic therapy clinical trials Diseases of the digestive system. Gastroenterology RC799-869 Diaz Soto MP Lim JK Evaluating the Therapeutic Potential of Cenicriviroc in the Treatment of Nonalcoholic Steatohepatitis with Fibrosis: A Brief Report on Emerging Data
description	Maria Paula Diaz Soto,1 Joseph K Lim2 1Department of Medicine, Yale School of Medicine, New Haven, CT, USA; 2Yale Liver Center and Section of Digestive Diseases, Yale School of Medicine, New Haven, CT, USACorrespondence: Joseph K LimProfessor of Medicine, Yale Liver Center and Section of Digestive Diseases, Yale School of Medicine, 333 Cedar Street, LMP 1080, New Haven, CT 06520-8019, USATel +1 (203) 737-6063Fax +1 (203) 785-7273Email joseph.lim@yale.eduAbstract: Non-alcoholic steatohepatitis (NASH) is associated with significant morbidity and mortality due to liver cirrhosis, liver failure, and hepatocellular carcinoma, and represents a leading indication for liver transplantation in the United States (U.S.). A growing spectrum of novel therapies are currently in clinical development and target several mechanisms of action which address hepatic steatosis, steatohepatitis, and hepatic fibrosis. Cenicriviroc (Allergan, Dublin, Ireland) is a novel oral antagonist of CC-motif chemokine receptors 2 and 5 (CCR2/5) which have demonstrated expression on circulating monocytes and Kupffer cells. Preclinical models have confirmed that CCR2/5 antagonism may block fat accumulation and Kupffer cell activation and disrupt monocyte/macrophage recruitment and hepatic stellate cell activation responsible for fibrogenesis. Herein we review results from the phase 2b CENTAUR trial and study designs for the phase 2b TANDEM and phase 3 AURORA trials and discuss the potential role of cenicriviroc in future pharmacotherapy for NASH fibrosis.Keywords: cenicriviroc, fatty liver, non-alcoholic steatohepatitis, liver fibrosis, antifibrotic therapy, clinical trials
format	article
author	Diaz Soto MP Lim JK
author_facet	Diaz Soto MP Lim JK
author_sort	Diaz Soto MP
title	Evaluating the Therapeutic Potential of Cenicriviroc in the Treatment of Nonalcoholic Steatohepatitis with Fibrosis: A Brief Report on Emerging Data
title_short	Evaluating the Therapeutic Potential of Cenicriviroc in the Treatment of Nonalcoholic Steatohepatitis with Fibrosis: A Brief Report on Emerging Data
title_full	Evaluating the Therapeutic Potential of Cenicriviroc in the Treatment of Nonalcoholic Steatohepatitis with Fibrosis: A Brief Report on Emerging Data
title_fullStr	Evaluating the Therapeutic Potential of Cenicriviroc in the Treatment of Nonalcoholic Steatohepatitis with Fibrosis: A Brief Report on Emerging Data
title_full_unstemmed	Evaluating the Therapeutic Potential of Cenicriviroc in the Treatment of Nonalcoholic Steatohepatitis with Fibrosis: A Brief Report on Emerging Data
title_sort	evaluating the therapeutic potential of cenicriviroc in the treatment of nonalcoholic steatohepatitis with fibrosis: a brief report on emerging data
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/4cb2a65da7ce4a4da3a22e9ab8eb02c3
work_keys_str_mv	AT diazsotomp evaluatingthetherapeuticpotentialofcenicrivirocinthetreatmentofnonalcoholicsteatohepatitiswithfibrosisabriefreportonemergingdata AT limjk evaluatingthetherapeuticpotentialofcenicrivirocinthetreatmentofnonalcoholicsteatohepatitiswithfibrosisabriefreportonemergingdata
_version_	1718396223818301440

Evaluating the Therapeutic Potential of Cenicriviroc in the Treatment of Nonalcoholic Steatohepatitis with Fibrosis: A Brief Report on Emerging Data

Ejemplares similares